The controlling shareholder of weight-loss drug maker Novo Nordisk on Monday mentioned it’s shopping for a supplier of drug manufacturing for $16.5 billion.
Novo Holdings, the controlling shareholder of Novo Nordisk
NVO,
mentioned it’s shopping for Catalent
CTLT,
for $16.5 billion in money, or $63.50 per Catalent share, a 16.5% premium to Friday’s shut.
Catalent inventory rose 13% in premarket commerce to $61.48.
The deal is a 39% premium to Catalent’s shut earlier than it introduced a strategic evaluation.
The deal will see Novo promote three fill-finish websites to Novo Nordisk shortly after the deal closes. Novo Nordisk has been struggling to satisfy demand for its widespread injectable weight-loss medication.
Catalent has greater than 50 websites globally.
Catalent investor Elliott Funding Administration mentioned it helps the deal.
Novo Holdings had property of €108 billion on the finish of 2022.